With $575 million in facility-specific investment, this project clears AFT's $100 million investment threshold (AFT includes any project meeting $100 million in facility-specific investment OR 100 permanent operating jobs). It is also confirmed by official public sources and involves a physical manufacturing facility in the United States.
View full methodology →The pharmaceuticals context.
Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.
At a glance
- Company
- Roche Group (Spark Therapeutics)
- Industry
- Pharmaceuticals
- Location
- Philadelphia, Pennsylvania
- Investment
- $575.0M
- Permanent jobs announced
- Not disclosed
- Status
- Under Construction
- Announced
- Dec 17, 2021
- Opening timeline
- Not yet announced
- Added to tracker
- Sep 1, 2026
Official references
- Spark Therapeutics and Drexel University's December 17, 2021 Philadelphia gene-therapy center announcement https://drexel.edu/news/archive/2021/december/spark-therapeutics-gene-therapy-innovation-center
- Hunter Roberts' project profile confirming cGMP manufacturing suites and Spark ownership https://www.hrcg.com/projects/spark-therapeutics-gene-therapy/
- Roche's Pennsylvania research-and-development location profile https://www.roche.com/innovation/structure/rnd-locations/pharma-philadelphia
Cite this project
American Factory Tracker. "Philadelphia Gene Therapy Innovation Center — Roche Group, Philadelphia, PA." https://americanfactorytracker.com/projects/roche-spark-philadelphia-gene-therapy-innovation-center. Accessed November 5, 2026.
Please also cite the original sources listed above for underlying figures.